Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT05231135
Recruiting Observational

A Registry Study on HIV-related Lymphoma

NCT05231135 · tracked via the Priya Life Science Spain tracker
Sponsor
Rotkreuzklinikum München gGmbH
Phase
Observational
Started
2021-08-25
Last updated
2023-04-06

Condition(s) studied

AIDS Related LymphomaHIV Related Lymphoma

Study summary

Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma * HIV-infection at time of lymphoma diagnosis * Lymphoma diagnosis since 01.01.2010 * Adult patients ≥ 18 years * Written informed consent Exclusion Criteria: * HIV-diagnosis \> 3 months after the diagnosis of malignant lymphoma * Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)

Primary outcome measure(s)

  • 2-year overall survival (OS) — 2 years
    OS measured from the date of diagnosis to last follow-up or to death from any cause.
  • 2-year progression-free survival (PFS) — 2 years
    PFS calculated from the date of diagnosis to the time of progression, relapse, or death.

Trial sites (6)

FacilityCityRegionStatus
Red Cross Hospital Munich Munich Select One Option Recruiting
University Hospital Cologne Cologne Germany Recruiting
Amsterdam University Medical Centers Amsterdam Netherlands Not Yet Recruiting
Hospital de la Santa Creu i Sant Pau Barcelona Spain Recruiting
Hospital Universitario de Salamanca Salamanca Spain Recruiting
University Hospital of Wales Cardiff United Kingdom Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05231135 on ClinicalTrials.gov ↗ ← All trials in Spain